Fig. 5
From: GAS6-based CAR-T cells exhibit potent antitumor activity against pancreatic cancer
Antitumor effects of GAS6-CAR-T cells are analyzed in vivo. A Photographs of NCG mice subcutaneously injected with 5 × 105 PANC1 cells; after receiving CAR-T-cell treatment, tumor volumes were monitored with bioluminescence at the indicated times. B Quantification of tumor bioluminescence levels (n = 5–6). C DNA copies of Mock T cells and GAS6-CAR-T cells in peripheral blood of mice were determined by real-time PCR. The expression of target genes was normalized GAPDH. 50 μL of venous blood collected from tail veins was collected after (days 7, 14, 21, 28, 35, 42) injecting GAS6-CAR-T cells into mice (n = 3–6). D Immunohistochemistry analysis of COX IV in tumor (n = 3), and the tumor weight at day 5 post-CAR-T cells infusion (the right). NCG mice subcutaneously injected with 5 × 105 PANC1 cells received an infusion of CAR-T cells (1 × 107 cells/mouse) at day 7, and the tumors were harvested after 5 days. E Immunohistochemistry analysis of CD3 in tumor (n = 3), and CD3 + T-cell numbers were counted in five randomly captured pictures of each mouse by ImageJ. F Co-immunofluorescence staining of AXL (green) and OCT4 (red) (n = 3)